Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wunderlich

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
Science (New York, N.Y.)|September 21, 2002
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley, John R Wunderlich, Paul F Robbins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanomaMark E Dudley, Colin A Gross, Robert P T Somerville, et al.
The Lancet. Oncology|April 12, 2017
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 studySmita S Chandran, Robert P T Somerville, James C Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with responsePaul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins, Richard A Morgan, Steven A Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2010
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanomaMark E Dudley, Colin A Gross, Michelle M Langhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.
Nature Genetics|March 31, 2009
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanomaLavanya H Palavalli, Todd D Prickett, John R Wunderlich, et al.
Cancer Discovery|June 6, 2019
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal CancersMaria R Parkhurst, Paul F Robbins, Eric Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaStephanie L Goff, Mark E Dudley, Deborah E Citrin, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Science (New York, N.Y.)|September 21, 2002
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley, John R Wunderlich, Paul F Robbins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanomaMark E Dudley, Colin A Gross, Robert P T Somerville, et al.
The Lancet. Oncology|April 12, 2017
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 studySmita S Chandran, Robert P T Somerville, James C Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2014
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with responsePaul F Robbins, Sadik H Kassim, Thai L N Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins, Richard A Morgan, Steven A Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2010
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanomaMark E Dudley, Colin A Gross, Michelle M Langhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.
Nature Genetics|March 31, 2009
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanomaLavanya H Palavalli, Todd D Prickett, John R Wunderlich, et al.
Cancer Discovery|June 6, 2019
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal CancersMaria R Parkhurst, Paul F Robbins, Eric Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaStephanie L Goff, Mark E Dudley, Deborah E Citrin, et al.
Pageof 15